- ¥158bn
- ¥108bn
- ¥97bn
Brief: Kissei Pharmaceutical Co Ltd To Buy Back Up To 4.34% Of Own Shares Worth 6 Billion Yen
Table: Kissei Pharm -2022/23 parent results
Table: Kissei Pharm -2022/23 group results
Table: Kissei Pharm -2022/23 group forecast
Launches Tavalisse Tab. 100Mg And 150Mg, An Oral Spleen Tyrosine Kinase Inhibitor, In Japan For Chronic Itp
Table: Kissei Pharm - 9-MTH group results
Marketing Authorization Approval In Japan For Tavalisse Tab. 100Mg And 150Mg, An Oral Spleen Tyrosine Kinase Inhibitor
Table: Kissei Pharm - 6-MTH group results
Brief: Kissei Pharmaceutical: Signed Technology Licensing Agreement With Taiwan's Synmosa Biopharma Over Gnrh Antagonist 'Linzagolix'
2022 6-month group forecast
Table: Kissei Pharm -Q1 group results
ObsEva shares plunge after bankruptcy filing
Table: Kissei Pharm -2021/22 group results
Table: Kissei Pharm -2021/22 parent results
Table: Kissei Pharm -2021/22 group forecast
Table: Kissei Pharm - 9-MTH group results
Table: Kissei Pharm - 9-MTH group results
Table: Kissei Pharm - 6-MTH group results
2021 6-month group forecast